AstraZeneca, a pharmaceutical company working with the University of Oxford to develop a COVID-19 vaccine, has announced that it will resume trials of a potential vaccine candidate. The trials were temporarily suspended by the UK drug regulator after a patient reported side-effects from the vaccine. So far, up to 18,000 people from the UK, Brazil, South Africa, and the United States have received the vaccine.
The University of Oxford and AstraZeneca vaccine is one of nine candidates being developed under the global COVAX Initiative, which is working to ensure equitable access to any new COVID-19 vaccine. If any of these vaccines are found to be safe, up to 100 million doses will be made available to low- and middle-income economies at just US$3 per dose, through the COVAX Facility.